BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, April 23, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
May 17, 2001
View Archived Issues
NIH licensing opportunity: HIV fusion proteins with increased immunogenicity
Read More
Licensing opportunity from NIH: E-selectin as treatment/prevention for brain injury
Read More
Tissue distribution and toxicity of EpiGenesis's RASON assessed
Read More
phVEGF-2 therapy shows promising results in human pilot study
Read More
New selective inhibitor of T-cell IL-5 synthesis promising for eosinophilic inflammation
Read More
Cytokine delivery using a biodegradable polymer system promotes bone formation and repair
Read More
Clinical trial results with Thalomid in early-stage and refractory multiple myeloma reported
Read More
Carafiban maleate, an orally active fibrinogen antagonist with clinical potential
Read More
Preclinical data support IL-13 receptor as a target for the therapy of glioblastoma
Read More
Eligix to begin phase III evaluation of BCell-HDM system
Read More
Murine and monkey studies demonstrate effective stem cell mobilization with SB-251353
Read More
XTL-001 enters phase II trial for chronic hepatitis B
Read More
BioSante begins phase II trial of testosterone gel for treatment of FSD
Read More
Phytera and Gemin X establish alliance for discovery of novel anticancer agents
Read More
Intellivax now part of ID Biomedical
Read More
ConjuChem completes phase I trial of anticlotting compound
Read More
Antitumor efficacy of SarCNU correlated with EMT and MGMT expression
Read More
Biomed-101 increases drug tolerance in phase I renal cancer trial
Read More
BioMedicines completes phase II enrollment of U.S. interferon omega trial
Read More
Serono and Alkermes to develop sustained-release formulation of rhFSH
Read More
EMD-221963, a representative NHE-3 inhibitor from Merck KGaA
Read More
New antiarrhythmic agents designed by Nissan to have fewer side effects
Read More
Highly effective HIV protease inhibitors designed by Tibotec and NIH
Read More
Novo Nordisk presents new compounds for diabetes and related disorders
Read More
Substituted biphenyls act as glucagon receptor antagonists, as reported by Bayer
Read More
Neurogen and Pfizer codevelop new NPY Y1 antagonists, describe potential uses
Read More
Company Profile: Lapid Pharmaceuticals
Read More